(firstQuint)DS-5565 Phase III Study for Post-herpetic Neuralgia.

 [Double Blind Phase] The primary objective is to compare change in the Average Daily Pain Score (ADPS) from baseline to Week 14 in Asian subjects with PHN receiving DS-5565 versus placebo.

 [Open Extension Phase] The objective is to assess the long-term safety and efficacy of DS-5565 in subjects with PHN.

.

 DS-5565 Phase III Study for Post-herpetic Neuralgia@highlight

Investigate the efficacy and safety of DS-5565 in subjects with Post-Herpetic Neuralgia (PHN) in comparison to placebo